Order Article Reprints

Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, et al. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. Pharmaceutics. 2022; 14(9):1844. https://doi.org/10.3390/pharmaceutics14091844

Rodier, Thomas, Alicja Puszkiel, Evelina Cardoso, David Balakirouchenane, Céline Narjoz, Jennifer Arrondeau, Vincent Fallet, Nihel Khoudour, Monia Guidi, Michel Vidal, and et al. 2022. "Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer" Pharmaceutics 14, no. 9: 1844. https://doi.org/10.3390/pharmaceutics14091844

Rodier, T., Puszkiel, A., Cardoso, E., Balakirouchenane, D., Narjoz, C., Arrondeau, J., Fallet, V., Khoudour, N., Guidi, M., Vidal, M., Declèves, X., Csajka, C., Alexandre, J., Cadranel, J., Fabre, E., Wislez, M., Goldwasser, F., & Blanchet, B. (2022). Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. Pharmaceutics, 14(9), 1844. https://doi.org/10.3390/pharmaceutics14091844